Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer

Journal of Clinical Oncology

Volumn 23, Issue 21, 2005, Pages 4719-4725

  Camidge, Ross ^a   Reigner, Bruno ^a   Cassidy, Jim ^a   Grange, Susan ^a   Abt, Markus ^a   Weidekamm, Erhard ^a   Jodrell, Duncan ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; CAPECITABINE; DRUG METABOLITE; VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; PHYTOMENADIONE;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENTIATION; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SINGLE DRUG DOSE; BLOOD; HALF LIFE TIME; METABOLISM; MIDDLE AGED; NEOPLASM; PROTHROMBIN TIME;

ADULT; ANTICOAGULANTS; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DRUG SYNERGISM; FACTOR VII; HALF-LIFE; HUMANS; MIDDLE AGED; NEOPLASMS; PROTHROMBIN TIME; VITAMIN K 1; WARFARIN;

EID: 23044454675     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.09.129     Document Type: Article

References (20)

1. Pentheroudakis G, Twelves C: The rational development of capecitabine from the laboratory to the clinic. Anticancer Res 22:3589-3596, 2002
2. Copur MS, Ledakis P, Bolton M, et al: An adverse interaction between warfarin and capecitabine: A case report and review of the literature. Clin Colorectal Cancer 1:182-184, 2001
3. Buyck HC, Buckley N, Leslie MD, et al: Capecitabine-induced potentiation of warfarin. Clin Oncol (R Coll Radiol) 15:297, 2003 (letter)
4. Benedetti F: Important Prescribing Information: Potential Xeloda Interaction with Coumarin Derivatives, http://www.fda.gov/medwatch/safety/1999/ xeloda.htm
5. Reigner B, Blesch K, Weidekamm E: Clinical Pharmacokinetics of capecitabine. Clin Pharmacokinet 40:85-104, 2001
6. Gibaldi M, Perrier D: Pharmacokinetics. New York, NY, Marcel Dekker, 1982, pp 409-417
7. Schuirmann DJ: A comparison of the two one-sided tests procedure and the power approach for assessing the bioequivalence of average bioavailability. J Pharmacokinet Biopharm 15:657-680, 1987
8. Wittowsky AK: Warfarin and other coumarin derivatives: Pharmacokinetics, pharmacodynamics, and drug interactions. Seminars in Vascular Medicine 3:221-230, 2003
9. O'Reilly RA, Aggeler PM, Leong LS: Studies on the coumarin anticoagulant drugs: The pharmacodynamics of warfarin in man. J Clin Invest 42:1542-1551, 1963
10. Holford IM: Clinical pharmacokinetics and pharmacodynamics of warfarin. Clin Pharmacokinet 11:483-504, 1986
11. Baron JA, Gridley G, Weiderpass E, et al: Venous thromboembolism and cancer. Lancet 351:1077-1080, 1998
12. Mousa SA: Anticoagulants in thrombosis and cancer: The missing link. Semin Thromb Hemost 28:45-52, 2002
13. Masci G, Magagnoli M, Zucali PA, et al: Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: Can it be safely administered with fluorouracil-based chemotherapy? J Clin Oncol 21:736-739, 2003
14. Schuller J, Cassidy J, Dumont E, et al: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291-297, 2000
15. Magagnoli M, Masci G, Carnaghi C, et al: Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen. Ann Oncol 14:959-960, 2003
16. Kolesar JM, Johnson CL, Freeberg BL, et al: Warfarin-5-FU interaction: A consecutive case series. Pharmacotherapy 19:1445-1449, 1999
17. Brown MC: An adverse interaction between warfarin and 5-fluorouracil: Case report and review of the literature. Chemotherapy 45: 392-395, 1999
18. Afsar A, Lee C, Riddick DS: Modulation of expression of constitutive rat hepatic cytochrome P450 isozymes by 5-fluouracil. Can J Physiol Pharmacol 74:150-156, 1996
19. Brown MC: Multisite mucous membrane bleeding due to a possible interaction between warfarin and 5-fluoruracil. Pharmacotherapy 17: 631-633, 1997
20. Tomasevic Z, Jelic S, Filipovic-Ljeskovic I, et al: Could capecitabine related hyperbilirubinaemia be a consequence of haemolysis? Proc Am Soc Clin One 21:88b, 2002 (abstr 2166)